Back to results
US 2026/0275332 A1Published application
Class 2, type v crispr systems
AssigneeMetagenomi Therapeutics, Inc.
InventorsBrian C. Thomas, Lisa Alexander, Molly Brothers, Christopher Brown, Dominic Castanzo, Cindy Castelle, Daniela S.A. Goltsman, Liliana Gonzalez-Osorio, Paula B. Matheus Carnevali
Life of this patent
Estimating the term…
Abstract
Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful for gene editing.
Claims32
An engineered nuclease system comprising:
- a) an endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs:
- 57, 31, 1-30, 32-56, 58-325, 420-431, 476-624, 629, 1065-1090, 1114-1118, 1746-1752, and 1842-1872;
- and
- b) an engineered guide polynucleotide configured to form a complex with the endonuclease and to hybridize to a target nucleic acid sequence.
1 more element
(canceled)
(canceled)
(canceled)
11-12. (canceled)
An engineered nuclease system comprising:
- (i) a) an endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs:
- 6-14;
- and
- b) an engineered guide polynucleotide configured to form a complex with the endonuclease and hybridize to a target nucleic acid sequence, the engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs:
- 333-335 and 355-357;
- (ii) a) an endonuclease comprising a sequence having at least 80% sequence identity to ID NO:
- 15;
- and
- b) an engineered guide polynucleotide configured to form a complex with the endonuclease and hybridize to a target nucleic acid sequence, the engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs:
- 410-411;
- (iii) a) an endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs:
- 16-29;
- and
- b) an engineered guide polynucleotide configured to form a complex with the endonuclease and hybridize to a target nucleic acid sequence, the engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs:
- 346-347, 368-369, and 412-413;
- (iv) a) an endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs:
- 57, 31, 1-30, 32-56, 58-150, 420-431, 476-624, and 629;
- and
- b) an engineered guide polynucleotide configured to form a complex with the endonuclease and hybridize to a target nucleic acid sequence, the engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs:
- 326-332, 336-345, 348-354, 358-367, 414-419, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458, 460, 462, 464, 466, 468, 470, 472, 474, 647-766, and 1697-1731;
- or
- (v) a) an endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs:
- 1065-1090, 1114-1118, and 1746-1752;
- and
- b) an engineered guide polynucleotide configured to form a complex with the endonuclease and hybridize to a target nucleic acid sequence, the engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs:
- 1091-1113, 1119-1120, and 1876.
23 more elements
18-31. (canceled)
33-37. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
50-63. (canceled)
Dependencies are inferred from the claim text.